AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04510012 — intervention group
Intervention type: OTHER
Intervention: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
Description: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
Study NCT03704467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: Participants received 90 milligrams per square meter (mg/m\^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m\^2, or 40 mg/m\^2.
Study NCT03704467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
Study NCT03704467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
Study NCT00283452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling with written materials
Description: Participation in phone/mail counseling to maintain physical activity
Study NCT01691209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix (BAY81-2996)
Description: Topical formulation applied to the skin
Study NCT01691209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Hydrocortison cream
Description: 1% Hydrocortison cream applied to the skin
Study NCT03231605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
Study NCT03231605 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A Vaccine
Description: Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
Study NCT03092921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Mask Seal
Description: Investigative Mask Seal to be used for OSA therapy
Study NCT03092921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Mask
Description: Investigative Mask to be used for OSA therapy
Study NCT02745444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: low-calorie formula diet
Study NCT02745444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: protein-restricted diet
Study NCT00967590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5036505
Description: 380mg iv infusion once weekly for 8 weeks
Study NCT00967590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: iv infusion once weekly for 8 weeks
Study NCT03228927 — intervention group
Intervention type: OTHER
Intervention: comparison of twin A to twin B
Description: Comparison of Twin A to Twin B
Study NCT01666496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Video Game
Description: Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
Study NCT01666496 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Off the Shelf Video Game
Description: Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
Study NCT02097004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: once weekly 180 μg subcutaneous injection for 48 weeks
Study NCT02097004 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: once weekly 180 μg subcutaneous injection for 48 weeks
Study NCT02097004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV vaccination
Description: 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
Study NCT03432117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Responsive respiratory rehabilitation
Description: The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
Study NCT02208986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Triptorelin is given by s.c injection for ovulation triggering.
Study NCT00190190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With Peeling of Limiting the Intern of the Retina
Description: With Peeling of Limiting the Intern of the Retina
Study NCT00190190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal limiting membrane peeling
Description: Traditional Procedure Without Peeling of Limiting
Study NCT02323516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid + loperamide
Description: In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
Study NCT02323516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diosmectite + loperamide
Description: In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
Study NCT01913925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tyrosine-Containing Food Bar
Study NCT03431506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular rehabilitation
Description: Vestibular Rehabilitation Exercises
Study NCT03431506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: Vestibular Rehabilitation Exercises
Study NCT01944488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: 100 µg/m2 body surface max 100 µg i.v.
Study NCT01500941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
Study NCT01500941 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: sachets
Study NCT03518489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lappaconitine Adhesive Patch
Description: to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain
Study NCT03518489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard care will include mouth wash with antibiotics.
Study NCT02480062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mWELLCARE
Description: mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
Study NCT02480062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care at the community health centers
Study NCT03662555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions.
Study NCT03662555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions.
Study NCT00493155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1530
Description: Administered po at escalating doses (10 cohorts)
Study NCT05097157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenza
Description: Subjects are treated with the Potenza™ device if they present with conditions such as, but not limited to: wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, or loose skin on the face, neck and/or body.
Study NCT03809247 — intervention group
Intervention type: OTHER
Description: have no any intervention
Study NCT00770224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00770224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tositumomab
Study NCT00770224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00770224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Study NCT00770224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT02097004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Continue Entecavir(0.5mg) for 100 weeks
Study NCT02097004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Continue Entecavir(0.5mg) for 100 weeks
Study NCT00770224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Study NCT00770224 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tositumomab
Study NCT04186663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: 38% aqueous silver diamine fluoride \[Ag(NH3)\]2F, CAS RN 33040-28-7
Study NCT04545034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water aerobic exercise
Description: The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
Study NCT01784614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Solution
Description: Administered orally as reconstituted solution
Study NCT01784614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Capsule
Description: Administered orally as a capsule
Study NCT01784614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Solution
Description: Administered orally as solution
Study NCT01784614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Solution
Description: Administered orally as solution
Study NCT01784614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Capsule
Description: Administered orally as a capsule
Study NCT01784614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Administered orally as a capsule
Study NCT01484561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CP-690,550 or Placebo
Description: CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
Study NCT01484561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID orally, approximately 72 days
Study NCT02456454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Liquid risperidone
Study NCT02456454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Liquid valproic acid
Study NCT02456454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04058158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB12 (proposed eculizumab biosimilar)
Description: 600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
Study NCT04058158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliris (eculizumab)
Description: 600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
Study NCT02036268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: Standard ostomy education
Study NCT02036268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard ostomy education
Study NCT02036268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Education
Description: In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
Study NCT02036268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-week Post Operative Education
Description: In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
Study NCT05204758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM Formula
Description: three packages of TCM preparations with each meal three times a day
Study NCT05204758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three packages of placebo preparations with each meal three times a day
Study NCT04125875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrogastrogram(EGG)
Description: Heart Rate Variability
Study NCT04125875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate Variability(HRV)
Description: Heart Rate Variability
Study NCT00291187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg VEC-162
Description: 20 mg VEC-162
Study NCT00291187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg VEC-162
Description: 50 mg VEC-162
Study NCT00291187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg VEC-162
Description: 100 mg VEC-162
Study NCT00291187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02361489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-Go
Description: Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
Study NCT01068613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX028
Description: QAX028 60 mcg via inhalation device
Study NCT01068613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX028
Description: QAX028 20 mcg via inhalation device
Study NCT01068613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium via inhalation device
Study NCT01068613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QAX028 via inhalation device
Study NCT03356808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lung cancer-specific T cells
Description: 1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
Study NCT04663542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immobilization duration
Description: brace immobilization duration after open surgery for Achilles tendon rupture
Study NCT04663542 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: immobilization duration
Description: brace immobilization duration after open surgery for Achilles tendon rupture
Study NCT01852916 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
Study NCT01852916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHFOV
Description: Nasal High Frequency Oscillatory Ventilation
Study NCT04324775 — intervention group
Intervention type: OTHER
Intervention: Exercise + Manual Lymphatic Drainage
Description: Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes
Study NCT04324775 — intervention group
Intervention type: OTHER
Intervention: Exercise + Swedish massage
Description: Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
Study NCT02260388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Study NCT02260388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT02260388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Study NCT02260388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Study NCT04077762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Access
Description: Radial Access
Study NCT04077762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: State-of-the-art femoral access with 18 gauge needle
Description: State-of-the-art femoral access with 18 gauge needle
Study NCT04077762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: State-of-the-art femoral access with 21 gauge needle
Description: State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
Study NCT04458545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxy(Gly)4-sKLH vaccine - Low Dose
Description: Oxy(Gly)4-sKLH vaccine - Low Dose
Study NCT01913925 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bar
Study NCT01470911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB010
Description: Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL.
Study NCT01470911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.